NCT01597388 2026-02-24
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
AstraZeneca
Phase 1 Completed
Clinical Trials
8 trialsNCT02546661 2025-12-29
BISCAY
AstraZeneca
Phase 1 Active not recruiting
NCT03334617 2025-10-27
HUDSON
AstraZeneca
Phase 2 Active not recruiting
NCT02398747 2024-12-17
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT02599714 2024-06-06
PASTOR
AstraZeneca
Phase 1 Completed
NCT03205046 2021-01-06
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Acerta Pharma BV
Phase 1/2 Terminated
NCT02780830 2016-09-15
INHIBITOR
AstraZeneca
Phase 1 Withdrawn
NCT01026402 2016-02-11
Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014
AstraZeneca
Phase 1 Completed